Scynexis plans SCY-770 Phase II start and names CFO
Scynexis said its SCY-770 Phase II trial for ADPKD is due to start by year-end, with an interim efficacy readout expected next year. The company also named Sanjay Subramanian as CFO effective Sept 9, 2026, as Ivor Macleod retires.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.